IL17A and psoriasis: Regarding anti‐IL‐17 inhibitors, a recent study including 114 elderly patients showed that these drugs were an effective and safe therapeutic option for patients with psoriasis aged ≥ 65 years, with low rates of only mild AEs; however, the discontinuation rate was 28.9%, mostly related to psoriasis relapses.30